Resource impact statement

No resource impact is anticipated

We do not expect this guidance to have a significant impact on resources that is, it will be less than £5m per year in England (or £9,100 per 100,000 population). We do not think practice will change substantially as a result of this guidance and the cost of treatment is low.

The guidance:

  • aligns NICE technology appraisal guidance on the use of bisphosphonates for preventing osteoporotic fragility fractures with NICE's guideline on osteoporosis: assessing the risk of fragility fracture
  • The previous NICE technology appraisal guidance TA160 and TA161 did not:
    • include recommendations for men
    • cover bisphosphonate treatments available, such as ibandronic acid and zoledronic acid.

The technologies are commissioned by clinical commissioning groups. Providers are NHS hospital trusts and primary care.

This page was last updated: 09 August 2017